

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)						
1. Name and Address of Reporting Person <sup>*</sup> Millard Jeffrey	2. Date of Event Requiring Statement (Month/Day/Year) 06/30/2021	3. Issuer Name and Ticker or Trading Symbol Ensysce Biosciences, Inc. [ENSC]				
(Last) (First) (Middle) C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201 (Street) LA JOLLA, CA 92037	- 00/30/2021	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director10% Owner XOfficer (give titleOther (specify below)Other (specify below)Other (specify DirectorOther (specify)Other (specify)Othe		er	<ul> <li>5. If Amendment, Date Original Filed(Month/Day/Year)</li> <li>6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person  Form filed by More than One Reporting Person</li> </ul>	
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned					
1.Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Instr. 4)		4. Nature of Indirect Beneficial Ownership (Instr. 5)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	and Expiration Date		3. Title and Amount of		4. Conversion 5. Ownership		6. Nature of Indirect Beneficial	
(Instr. 4)			d Expiration Date Securities Underlying Derivative o		or Exercise	Form of	Ownership	
			Security		Price of	Derivative	(Instr. 5)	
			(Instr. 4)		Derivative	Security: Direct		
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	2	(D) or Indirect (I) (Instr. 5)		

## **Reporting Owners**

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Millard Jeffrey C/O ENSYSCE BIOSCIENCES, INC. 7946 IVANHOE AVENUE, SUITE 201 LA JOLLA, CA 92037			Chief Operating Officer		

### **Signatures**

/s/ Jeffrey Millard	07/02/2021	
**Signature of Reporting Person	Date	

# **Explanation of Responses:**

### No securities are beneficially owned

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

#### **Remarks:**

No Securities Beneficially Owned

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.